BR112018000568A2 - antagonistas do receptor 5-ht6 para uso no tratamento da doença de alzheimer com apatia como comorbidade - Google Patents
antagonistas do receptor 5-ht6 para uso no tratamento da doença de alzheimer com apatia como comorbidadeInfo
- Publication number
- BR112018000568A2 BR112018000568A2 BR112018000568A BR112018000568A BR112018000568A2 BR 112018000568 A2 BR112018000568 A2 BR 112018000568A2 BR 112018000568 A BR112018000568 A BR 112018000568A BR 112018000568 A BR112018000568 A BR 112018000568A BR 112018000568 A2 BR112018000568 A2 BR 112018000568A2
- Authority
- BR
- Brazil
- Prior art keywords
- apathy
- alzheimer
- disease
- treatment
- receptor antagonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Abstract
a presente invenção se relaciona com antagonistas do receptor 5-ht6 para o tratamento da doença de alzheimer com apatia comórbida compreendendo administração de uma dose eficaz de um antagonista do receptor 5-ht6 para melhorar ou aumentar o efeito de um inibidor de acetilcolinesterase.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201600286 | 2016-05-11 | ||
PCT/EP2017/060979 WO2017194496A1 (en) | 2016-05-11 | 2017-05-09 | 5ht6 receptor antagonists for use in the treatment of alzheimer's disease with apathy as comorbidity |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018000568A2 true BR112018000568A2 (pt) | 2018-09-11 |
Family
ID=58707519
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018000568A BR112018000568A2 (pt) | 2016-05-11 | 2017-05-09 | antagonistas do receptor 5-ht6 para uso no tratamento da doença de alzheimer com apatia como comorbidade |
Country Status (7)
Country | Link |
---|---|
US (1) | US10864191B2 (pt) |
EP (1) | EP3454848B1 (pt) |
JP (2) | JP6961622B2 (pt) |
CN (1) | CN109069466B (pt) |
BR (1) | BR112018000568A2 (pt) |
ES (1) | ES2826386T3 (pt) |
WO (1) | WO2017194496A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10864191B2 (en) * | 2016-05-11 | 2020-12-15 | H. Lundbeck A/S | 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity |
BR112019001145A2 (pt) | 2017-05-24 | 2019-04-30 | H. Lundbeck A/S | combinação de um antagonista do receptor 5-ht6 e de um inibidor de acetilcolinesterase para uso no tratamento da doença de alzheimer em uma subpopulação de pacientes portadores de alelos de apoe4 |
AU2020396396A1 (en) | 2019-12-02 | 2022-06-16 | Suven Life Sciences Limited | Methods for treating behavioral and psychological symptoms in patients with dementia |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2006641A (en) * | 1932-09-26 | 1935-07-02 | Charles E Johnson | Hydraulic tappet |
AU2002303094B2 (en) | 2001-03-29 | 2006-11-23 | Eli Lilly And Company | N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor |
PE20071143A1 (es) * | 2006-01-13 | 2008-01-20 | Wyeth Corp | Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6 |
AR061637A1 (es) * | 2006-06-26 | 2008-09-10 | Epix Delaware Inc | Composiciones y metodos de tratamiento de trastornos del snc |
EP2508177A1 (en) | 2007-12-12 | 2012-10-10 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
EP2248814A4 (en) | 2008-01-24 | 2011-01-12 | Alla Chem Llc | SUBSTITUTED CYCLOALKAN [E AND D] PYRAZOLO [1,5-A] PYRIMIDINES / ANTAGONISTS OF SEROTONIN 5-HT6 RECEPTORS AND PROCESS FOR THEIR PREPARATION AND THEIR USE |
EP2248817B1 (en) | 2008-01-24 | 2015-01-07 | Alla Chem, LLC. | Substituted 2-amino-3-sulfonyl-pyrazolo[1,5-a] pyrimidines/antagonists of serotonin 5-ht6 receptors, methods for the production and the use thereof |
RU2369600C1 (ru) | 2008-01-24 | 2009-10-10 | Андрей Александрович Иващенко | ЗАМЕЩЕННЫЕ 4-СУЛЬФОНИЛ-ПИРАЗОЛЫ И 3-СУЛЬФОНИЛ-ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ5-HT6 РЕЦЕПТОРОВ, АКТИВНЫЙ КОМПОНЕНТ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ЛЕКАРСТВЕННОЕ СРЕДСТВО И СПОСОБЫ ИХ ПОЛУЧЕНИЯ |
EP2248816B1 (en) | 2008-01-24 | 2014-10-22 | Alla Chem, LLC. | 2-ALKYLAMINO-3-ARYLSULFONYL-CYCLOALCANO [e OR d] PYRAZOLO[1,5-A]PYRIMIDINES AS ANTAGONISTS OF SEROTONIN 5-HT6 RECEPTORS, METHODS FOR THE PRODUCTION AND THE USE THEREOF |
JO3459B1 (ar) * | 2012-09-09 | 2020-07-05 | H Lundbeck As | تركيبات صيدلانية لعلاج مرض الزهايمر |
US10864191B2 (en) | 2016-05-11 | 2020-12-15 | H. Lundbeck A/S | 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity |
-
2017
- 2017-05-05 US US15/587,935 patent/US10864191B2/en active Active
- 2017-05-09 CN CN201780028711.1A patent/CN109069466B/zh active Active
- 2017-05-09 WO PCT/EP2017/060979 patent/WO2017194496A1/en unknown
- 2017-05-09 EP EP17723326.9A patent/EP3454848B1/en active Active
- 2017-05-09 ES ES17723326T patent/ES2826386T3/es active Active
- 2017-05-09 BR BR112018000568A patent/BR112018000568A2/pt not_active Application Discontinuation
- 2017-05-09 JP JP2018559275A patent/JP6961622B2/ja active Active
-
2021
- 2021-10-13 JP JP2021168436A patent/JP7217789B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
EP3454848A1 (en) | 2019-03-20 |
CN109069466A (zh) | 2018-12-21 |
ES2826386T3 (es) | 2021-05-18 |
JP2022009121A (ja) | 2022-01-14 |
WO2017194496A1 (en) | 2017-11-16 |
JP7217789B2 (ja) | 2023-02-03 |
CN109069466B (zh) | 2021-06-15 |
JP6961622B2 (ja) | 2021-11-05 |
JP2019518736A (ja) | 2019-07-04 |
US10864191B2 (en) | 2020-12-15 |
EP3454848B1 (en) | 2020-09-09 |
US20170326107A1 (en) | 2017-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124436T1 (el) | Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια | |
CY1121170T1 (el) | Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων | |
BR112018000691A2 (pt) | inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias | |
PH12016502167A1 (en) | Hdl theraphy markers | |
EA201691872A1 (ru) | Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств | |
MX2016012574A (es) | Compuestos heteroarilo sustituidos y metodos de uso. | |
DOP2016000226A (es) | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados | |
BR112017028140A2 (pt) | formulações farmacêuticas | |
BR112016028845A2 (pt) | composto, composição farmacêutica e uso de um composto | |
BR112017008045A2 (pt) | compostos como inibidores de nik | |
MY199091A (en) | Therapeutic compounds | |
BR112017005209A2 (pt) | compostos moduladores de pirrolopiridina substituída por metila e trifluorometila de rorc2 e seu uso | |
BR112017007704A2 (pt) | derivados de pirazolopirimidina como inibidores de nik | |
ECSP16008797A (es) | Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos | |
ECSP16078779A (es) | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados | |
MY201535A (en) | Therapeutic compounds | |
CL2016000325A1 (es) | Antagonistas de vía para tratar trastornos del sueño por cambio de fase | |
ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
BR112018069682A2 (pt) | métodos de tratamento para doenças colestáticas e fibróticas | |
BR112018000568A2 (pt) | antagonistas do receptor 5-ht6 para uso no tratamento da doença de alzheimer com apatia como comorbidade | |
BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
UY33529A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias? | |
BR112015024703A2 (pt) | formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose | |
ECSP16086232A (es) | (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
BR112018073419A2 (pt) | combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |